Evicenter
MarkdownMedical informationP&T meetings
VK2735

Chronic weight management

Last updated
184 sources

Clinical evidence

VANQUISH-1

39 evidence topics · 16 sources

Objective
Location and study date
Study design
Extension study after the 78-week treatment period
Eligibility criteria
Treatment
Study outcomes
Rationale for using percent change in body weight as the primary endpoint
Statistical analysis description
Number of participants (Planned and analyzed)
Planned participants per arm in the design poster
ArmPlanned participants
Placebo“n=1224”
VK2735 7.5 mg“n=816”
VK2735 12.5 mg“n=1224”
VK2735 17.5 mg“n=1224”
Description of analysis sets
Efficacy and safety analysis sets

No evidence found.

Results
Participant disposition
Baseline characteristics
Demographics and body size compared with NHANES
CharacteristicVANQUISH-1 (N=4660)NHANES
Age, mean (SD), years“50.4 (13.81)”“47.6 (13.97)”
Age 65 years or older“17%”“19%”
Sex, female to male“65%:35%”“51%:49%”
Waist circumference, mean (SD), cm“116.2 (16.13)”“109.2 (11.35)”
BMI, mean (SD), kg/m2“38.3 (7.31)”“33.7 (5.10)”
BMI 27 to less than 30 kg/m2“5%”“33%”
BMI 30 to less than 35 kg/m2“33%”“36%”
BMI 35 to less than 40 kg/m2“28%”“16%”
BMI 40 kg/m2 or higher“33%”“15%”
Age distribution compared with NHANES
Age group, yearsVANQUISH-1NHANES
18 to 34“15%”“28%”
35 to 44“21%”“20%”
45 to 54“24%”“16%”
55 to 64“23%”“17%”
65 to 74“15%”“12%”
Over 75“3%”“7%”
Race and ethnicity compared with NHANES
Race or ethnicityVANQUISH-1NHANES
Non-Hispanic White“56%”“60%”
Hispanic or Latino“21%”“18%”
Non-Hispanic Black“17%”“12%”
Non-Hispanic Asian“2%”“4%”
Other“4%”“6%”
Baseline laboratory values
Measurement, mean (SD)VANQUISH-1 (N=4660)
HbA1c, %“5.5 (0.40)”
Glucose, mg/dL“97.2 (11.18)”
Insulin, µIU/mL“16.4 (15.66)”
Total cholesterol, mg/dL“192.6 (39.69)”
Triglyceride, mg/dL“126.8 (61.85)”
hsCRP, mg/L“6.0 (8.82)”
Efficacy results

No evidence found.

Health-related quality of life and patient-reported outcomes

No evidence found.

Safety results

No evidence found.

Study limitations
Summary: limitations evident from the available VANQUISH-1 documents

VANQUISH-1 is ongoing, with primary completion estimated for July 2027 and data expected in the second half of 2027, so no efficacy, patient-reported outcome, or safety result is available. All available information comes from the ClinicalTrials.gov record, company press releases, an investor presentation, company call and conference transcripts, and two congress posters authored by company employees with or without study investigators; no peer-reviewed design or results publication was identified, and the ClinicalTrials.gov record has posted no results.

Reported enrollment differs between documents: the registry lists an estimated 4,500 participants, the enrollment release reported “approximately 4,650 adults”, the baseline poster reported 4,660 participants randomized from 138 sites, and later releases and the investor presentation describe approximately or more than 4,500. The registry lists 137 locations.

The 7.5 mg arm was planned to be smaller than the other arms (816 compared with 1,224 planned participants per arm), so estimates for that dose will be less precise. The trial enrolled participants without diabetes in the United States and Puerto Rico only; 65% of participants were women, and the mean BMI was 38.3 kg/m2, higher than the 33.7 kg/m2 of the NHANES comparison population. Prior use of GLP-1 receptor agonists or dual GLP-1/GIP receptor agonists within 6 months of screening was excluded. The company describes the blinded discontinuation rate only qualitatively. The device changed during the trial, from vial and syringe to an autoinjector introduced in the first quarter of 2026. The extension study, which adds every-other-week and monthly regimens, is expected to report in 2028 and will not inform the primary 78-week analysis.